Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study

M. A. Riedl, E. Aygören-Pürsün, J. Baker, H. Farkas, J. Anderson, J. A. Bernstein, L. Bouillet, P. Busse, M. Manning, M. Magerl, M. Gompels, A. P. Huissoon, H. Longhurst, W. Lumry, B. Ritchie, R. Shapiro, D. Soteres, A. Banerji, M. Cancian, D. T. JohnstonT. J. Craig, D. Launay, H. H. Li, M. Liebhaber, T. Nickel, J. Offenberger, W. Rae, R. Schrijvers, M. Triggiani, H. J. Wedner, S. Dobo, M. Cornpropst, D. Clemons, L. Fang, P. Collis, W. P. Sheridan, M. Maurer

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences